180,729 Shares in Qiagen (NYSE:QGEN) Purchased by Impax Asset Management Group plc

Impax Asset Management Group plc purchased a new stake in shares of Qiagen (NYSE:QGEN - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 180,729 shares of the company's stock, valued at approximately $8,236,000. Impax Asset Management Group plc owned 0.08% of Qiagen as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC lifted its position in shares of Qiagen by 806.5% during the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company's stock valued at $26,000 after buying an additional 500 shares in the last quarter. Toronto Dominion Bank purchased a new position in Qiagen during the second quarter valued at approximately $27,000. Massmutual Trust Co. FSB ADV boosted its position in shares of Qiagen by 39.8% in the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company's stock worth $39,000 after purchasing an additional 243 shares during the period. CWM LLC boosted its position in shares of Qiagen by 12.0% in the second quarter. CWM LLC now owns 2,505 shares of the company's stock worth $103,000 after purchasing an additional 269 shares during the period. Finally, Headlands Technologies LLC increased its stake in shares of Qiagen by 396.6% in the second quarter. Headlands Technologies LLC now owns 2,741 shares of the company's stock worth $113,000 after purchasing an additional 2,189 shares in the last quarter. Hedge funds and other institutional investors own 70.00% of the company's stock.

Qiagen Trading Down 1.9 %

Shares of NYSE:QGEN traded down $0.82 during trading on Friday, reaching $41.27. The company's stock had a trading volume of 1,234,315 shares, compared to its average volume of 1,164,011. The firm's 50 day simple moving average is $43.85 and its two-hundred day simple moving average is $43.75. The company has a current ratio of 2.17, a quick ratio of 1.46 and a debt-to-equity ratio of 0.39. Qiagen has a 12 month low of $39.03 and a 12 month high of $47.44. The stock has a market capitalization of $9.42 billion, a PE ratio of 105.82, a price-to-earnings-growth ratio of 3.24 and a beta of 0.41.

Analysts Set New Price Targets

Several research analysts recently weighed in on QGEN shares. Hsbc Global Res raised shares of Qiagen to a "hold" rating in a report on Thursday, October 17th. HSBC downgraded Qiagen from a "buy" rating to a "hold" rating and set a $49.00 price target for the company. in a research note on Thursday, October 17th. Finally, Robert W. Baird lifted their price objective on shares of Qiagen from $49.00 to $52.00 and gave the company an "outperform" rating in a research report on Friday, August 2nd. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $50.88.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.